ABSTRACT
41

BACKGROUND 42
Cryptococcosis is amongst the leading and 43 life-threatening opportunistic infection [1] . 44 The disease is caused by Cryptococcus 45 neoformans (C.
neoformans) and 46
Cryptococcus gattii (C. gattii), which are 47 vastly diagnosed among immune-48 compromised patients [2] . Mainly C. 49 neoformans, with three recognized 50 serotypes which are acknowledged as 51 serotype A, serotype D and the hybrid-52 AD [3] . Previously, these serotypes were 53 identified and differentiated by the 54 phenotypic approach [4] . Lately, are 55 identified by PCR assays [5] . More methods 56 of molecular assays are used to classify C. 57 neoformans serotypes [6] . The classification 58 is based on antigenic metamorphoses in 59 the polysaccharide capsule associated with 60 virulence factors [3, 7] . Prevalently found 61 circulating globally is serotype A, whereas 62 serotype D and AD hybrid circulating in 63 truncated numbers [1 -3] . Serotype A account 64 for more than 90% cases of cryptococcosis 65 in South Africa owing to the extraordinary 66 occurrence of HIV/AIDS [2, 8, 9, 10] . 67 68
To treat cryptococcosis, the most widely 69 used antifungal agents are amphotericin-B, 70 flucytosine, voriconazole and 71 fluconazole [9, 11] . Amphotericin-B is used 72 as the first line treatment but limited by 73 toxicity that requires laboratory 74 monitoring, voriconazole is limited to 75 private sectors in Africa [9] [10] [11] [12] . The  76  amalgamations  of  antifungals  are  77  recommended  for  induction  but  78 flucytosine is not available in resource-79 poor countries [12] . Unfortunately, these are 80 countries with a high incidence of 81 cryptococcosis [10] [11] [12] . All these antifungals  82  are also limited by emerging resistance  83  mechanisms such as the antigenic  84  polysaccharide capsule tolerance, the  85  mating gene types, the acid tolerant  86 abilities, and spores switching [12] . 87
Globally, 20-58% of resistance cases are 88 reported on cryptococcosis by means of 89 diverse studies, focusing on fluconazole . Emerging resistance on the other 91 cryptococcosis antifungals was not 92 reported [9, 15] . Furthermore, intrinsic and  93  acquired resistance mechanisms are all  94  associated with Cryptococci and the drugs  95  proneness  to  those  resistance  96 mechanisms [12, [16] [17] [18] . 97 98
The widespread use of fluconazole may 99 lead to the emergence of reduced 100 susceptibility [19, 20] . [21] . India ink (negative stain) 163 was done as described by Ogundeji (2013) 164 to verify the presence of capsule [22] . A and D [27] . [32] , and that of 63% by Favalessa 395 et al (2014) in West Brazil patients [33] .
396
Furthermore, a South African report of 397
Govender et al (2011) and (2013) showed 398 58% resistance to fluconazole [9, 25] . 399 400
Fluconazole resistance is based on the C. 401 neoformans mechanisms of action [8,16,-18] .
402
The [35] . In 448 our study, we didn't manage to find the 449 HIV status of our patients. [37] , whereas 467 Feretzaki et al (2014) in India reported that 468 serotype D requires very high inoculum to 469 disseminate and cause infections like 470 meningitis [38] . 
